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ing moderate HFRS cases and that A. agrarius instead of A.Jauicollis 
forms its rodent reservoir. Meanwhile, also in Germany, cases of 
human infections and HFRS caused by Dobrava virus were found. 
v] PVP-iodine (Betaisodona) destroys the 
infectivity of the respiratory syncytial virus and 
the corresponding inflammatory mediators 
B. Konig, K. Reimer, W. Fleischer, W. Konig, University 
Magdeburg, Imt. f.r Med. A.licrobiology, Magdebug, Germany 
Objectives: PVP-iodine has proven antiviral activity. Nonetheless, 
with regard to the respiratory syncytial virus (RSV), a loss in infec- 
tivity is not correlated with a loss in pathogenicity. In this regard, 
inactivated RSV, as well as other respiratory viruses, induces the 
release of huge amounts of pro-inflammatory cytokines from epithe- 
lial cells, from monocytes and &om neutrophilic granulocytes. We 
analyzed whether PVP-iodine is able to destroy the infectivity of 
RSV in combination with the prevention of inflammatory mediator 
induction. 
Methods: Purified RSV was incubated with buffer or with PVP- 
iodine at various dilutions (from 1:50 up to 1 : lOOO)  for 30 min up 
to 24 h. Thereafter, granulocytes, monocytes and epithelial cells 
(A549, HEp-2) were incubated with the untreated or with the treated 
RSV for 60 min. Then the RSV was removed and the incubation 
proceeded for a further 6 h and 18 h (granulocytes) or 24, 48 or 72 
h (monocytes, epithelial cells). The supernatants were assayed for the 
presence of RSV and pro-inflammatory cytokines. The cell pellets 
were analyzed for the presence of RSV-specific genomic and mRNA 
(SH genes), and for the mRNA of pro-inflammatory cytokines and 
housekeeping genes (18s RNA, B-actin, GAPDH). 
Results: The pretreatment of RSV with PVP-iodine (dilution of 
1:50) for 1 h was sufficient to destroy the infectivity of the virus. The 
pretreated RSV no longer induce the expression (mRNA) or release 
of pro-inflammatory cytokines (IL-6, IL-1, TNF-alpha, IL-8). The 
viability of the host cells was not affected. 
Conclusions: These data suggest the use of PVP-iodine as a ther- 
apeutic agent in infection 
Hepatitis 
I=] Acute viral hepatitis in drug addicts 
V. Nikolova, Z. Zasheva, N. Naidenova, G. Goranova 
Faculty, Sofia, Bulgaria 
Medkal 
Acute viral hepatitis (AVH) is extremely common in drug addcts. 
The aim of this study is to evaluate the clinical and laboratory find- 
ings as well as epidemiologic data of patients with AVH and drug 
addiction. 
Based on a prospective study, we have analyzed the course of AVH 
in 98 patients hospitalized in the Infectious Diseases Hospital during 
the period 1995-98, all with a history ofintravenous drug abuse from 
2-3 months to 5 years. The average age of the patients was 20,10 
years, the range 16-32 years. AVH A was proven in 3 patients, AVH 
B in 26 and AVH C in 44. Co-existent HBV and HCV infection 
was present in 15 patients, HAV and HCV in 8, HAV and HBV 
infection in 1, and HAV, HBV and HCV in 1. 
There were signs and symptoms of acute viral hepatitis in 92 
patients: malaise and fatigue, anorexia, nausea and vomiting, fever, 
myalgia, pains in the right hypochondrium, and jaundice. Six patients 
were asymptomatic. Slight hepatomegaly was observed in most 
patients but in those with concomitant alcohol consumption, liver 
enlargement was considerable. 
An anicteric course was observed in 17 patients. In 55 patients 
with AVH B or with double infection, the course of the disease was 
severe, with high levels of bilirubinemia (115-393 mmol/L) and 
increased serum transaminase activities (ASAT 180-1497 UI/L, 
ALAT 218-2127 UI/L). With 3 patients, encephalopathy developed 
and presented diagnostic problems, because of the similarities 
between its symptoms and symptoms of abstinence. The treatment 
of AVH in drug users was the same as the treatment of an acute liver 
disease, but ceasing narcotic use first was obligatory. 
In conclusion, we can say that AVH in drug addicts is a serious 
diagnostic and therapeutic problem. Co-existence of HBV and HCV 
infections presents severe clinical symptoms, expressing the general 
status of the patient. The outcome, especially in cases with HBV and 
HCV infection, is unknown. Chronic liver disease may develop. 
(p5061 Postmarketing safety of an aluminum-free, 
virosome-formulated hepatitis A vaccine-a 
Swiss multicenter study 
B. Beck', 8. Genton', C. Hatz', C. Herzog), B. Isenschmid3, L. 
Loutan4, R. Steffen", M. Zellmeyer'. 'Swiss Eopicol Institute, Basel, 
'Uriiuersity Hospital, Lausanne, 'Swiss Serum and kccine Institute, 
Bern, 4Uuiversity Hospiral, Geneva, 51nstitute o f  Social G Preventive 
Medicine, Uniuersify o f  Zurich, Zurich, Switzerland 
Objectives: To assess with closed versus open questioning the safety 
of a single priming or a booster dose of an aluminum-6ee, virosome- 
formulated hepatitis A vaccine. 
Methods: Travelers aged 1 year were enrolled who consulted the 
travel clinics at the four participating centers for a hepatitis A vacci- 
nation. After written consent was obtained, a single dose of vaccine 
(Epaxal Berna) was administered and the vaccinees were openly 
randomized to record the tolerability on diary cards with either 
closed (group A) or open questions (group B). All participants were 
carefully instructed on how to document the safety parameters 
during a 4-day observation period and asked to send the diary back 
after completion. 
Results: The study started in July 1998 and will enroll 2500 
subjects. Preliminary results of the analysis of the first 500 cards 
collected for one of the centers are as follows: 95.4% of the diaries 
were returned; 475 vaccinees were evaluable: 246 females, 229 males, 
age 35.9 (5-74) years. The rates of subjects reporting any local or 
systemic adverse events (AEs) were 32% and 35% for group A and 
24% and 22% for group B, respectively. 23% of subjects in group A 
reported systemic symptoms at baseline; in group B the baseline AE 
rate was not assessed. The rates of local or systemic AEs were not 
different following primary or booster doses. Over 95% of AEs were 
considered minor and there were no serious AEs. 
Conclusions: The closed questioning resulted in more AE 
reporting compared to the open questions. The preliminary evalua- 
tion shows an excellent tolerability of the aluminum-&ee, virosome- 
formulated hepatitis A vaccine. 
(p507( Prevalence of hepatitis A antibodies in a large 
sample of Belgian healthcare workers 
R. Vranckx', €? Jacques2, G. Moens*. 'Institute ofpublic Health, 
Brussels, 'University of l euuen ,  Belgium 
Objectives: Healthcare workers (HCW), especially females (e.g. 
pediatric nurses and day nursery workers), have been shown to be at 
risk for viral hepatitis A infections. In order to obtain a more precise 
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estimate of the risk in Belgian HCW, an age-specific seroprevalence 
study was set up. These data are compared with the age-specific sero- 
prevalence of anti-HAV in the general population that has been esti- 
mated recently. 
Methods: During 1996-97, a sample of employees in 22 general 
hospitals, geographically distributed over the Flemish and Brussels 
region, was tested for the presence of anti-HAV 
Results: Comparison of anti-HAV prevalences in H C W  and GII' 
significant differences only for age groups 25-34 and 35-44. Within 
the H C W  group in both the saine age groups, persons pedoriiiing 
catering tasks have the highest prevalences. This difference can be 
explained by socio-economic parameters, overrepresenting higher 
social class in highly educated HCW. 
Conclusions: T h e  number of unprotected young age group 
(24-45) individuals are niore important than in the general popula- 
tion. In view of the changing HAV cpideniiolology in western 
Europe, this nuinber of unprotected will rise in the coming years. In 
this context vaccination may become a suitable occupational health 
strateSy. 
Ip5081 HBV antigen-specific CD4 lymphocyte 
proliferation in children with chronic hepatitis 
B before and after treatment with IFN-alpha 
A. Szkaradkiewicz, A. Jopek, J. Wysocki, Z .  Muszynski. Karol 
Marcinkowski University (3 Medical Sciences in Poinuti, Polawd 
Objectives: Evaluation of therapeutic effects which followed IFN- 
alpha administration in a group of 15 children with chronic active 
hepatitis B (CAH) on  proliferative response of CD4 lyniphocytes 
exposed to nucleocapsid of  hepatitis B virus. 
Methods: 8-16-year-old children, all fulfilling classic criteria of 
CAH, were selected for treatment with INF-alpha (Intron A, 3 X  10" 
IU, 3 times a week for 20 weeks). C D 4  lymphocytes were isolated 
from peripheral blood with the imrnunomagnetic bead technique 
(Dynd). Proliferation of C D 4  lymphocytes, stimulated with rHBcAg 
(nig/mL), was evaluated aftcr 72 h using the cell proliferation ELISA 
system, version 2 (Biotrak). 
Results: Before treatment, CD4  lymphocytes isolated froin 4 
children manifested significant proliferation when exposed to 
rHBcAg (mean absorbance of 0.95?0.08), while no proliferative 
response could be detected in the remaining 11 patients (mean 
absorbance of O.32+O.06). In the group of 15 healthy control chil- 
dren the responses amounted to a mean of0.37?0.07. Following the 
treatnient of children, proliferation of their CD4 lyniphocytes did not 
significantly differ from results obtained before the tredtinent 
Conclusions: Therapy with IFN-alpha did not induce changes 
oJ>0.05) .  
in C1)4 lymphocyte reactivity to nucleocapsid of hepatitis €3 virus. 
[q Severe form of acute hepatitis B 
immunoregulatory treatment 
M. Andre, M. Andreychyn, I .  Ishchuk, I .  Hospodarskyy, Z 
Botsuk, N. Nychyk. Medira l  Acadmiy, Enlop i / ,  (Jkrainc 
126 patients with a severe form of acute hepatitis B in precoma 1 and 
I1 were observed. Conventional clinical, biochemical, iminuiiologic 
and instrumental assays were performed. In all the patients signs of a 
threatened coma were revealed such as fever, progressive weakness, 
nausea, sleep inversion, liver size reduction, aiid bilirubin-enzyme 
dissociation. Laboratory signs of tissue intoxication and inimunologic 
disorders usually occurred 2 -4  days before clinical syniptonis. It is 
useful to be able to forecast complications in time. 34 patients 
received conventional treatment including steroids. Besides conven- 
tional therapy, ornithine IV (5-20 g daily) and synthetic prostaglandin 
E-inisoprostol PO (200 nig t.i.d. before taking steroids) were 
prescribed in 92 patients. Faster clinical and biochemical impi-ove- 
inent was registered in the second group of patients. Ornithine 
coursed to clinical and laboratory disappearance. Misoprostol not 
only prevented the inucosal side effects ofsterolds but also had a posl- 
five influence on  the regulation of the iinniune system. Usc of 
prostaglandin E led to lymphocyte populations and the rcstitution of 
subpopulatioiis, imiiiunoregulatory indices normalization. The 
predominant niechanism of niisoprostol iminunotrope action is as a 
stimulant of T-suppressors. This is necessary in the case of a severe 
form of hepatitis B that occurs because of a hyposuppressive immune 
response. 
v1 Ten-year follow-up of children vaccinated 
against hepatitis 6 
L. Roznovsky', 1. Lochman', L. Pliskova', L. Lukacova', A. 
Zjevikova', I. Orsagova', A. Sulakova' . Ear-h iq  Hospifal Osrrava, 
'Dcpartnrenf of li$rtioirs Diseases, Osrrava, *Departmrtrt of I I ~ I T ~ U I J ~ I / ~ ~ ~ J ~  
and Aliergofqy): Osfraun, 'Deporfnrertf cf Cliniral Bioclwwistry, Hrniiir 
Krdlovi, Czccli Rq~u/dic 
Objectives: Peririatal transmission of hepatitis B virus, breakthrough 
infections aiid anti-HBs antibodies were investigated in children 
vaccinated against hepatitis B. 
Methods: Passive-active iminunization of 440 newborns against 
hepatitis B started in 1988. All mothers were HBsAg positive during 
pregnancy; 22 of them were also HUeAg positive. The children 
received HBIG at birth and three lO-kg doses of plasma-derived or 
recombinant vaccine at 0, 1 and 6 nionths (only 11 children of 
HbeAg-positive mothers at 0, 1 and 2 months). Blood samples were 
tested by ELISA for HBsAg, anti-1113s. anti-HBc and anti-1113e. 
The presence of hepatitis B virus (HBV) DNA was determined by 
polymerase chain reaction. 
Results: N o  perinatal transnmirsion of hepatitis B virus was proved 
in children. The presence of HBV DNA was investigated in umbil- 
ical blood or venous blood in 32 children younger than 1 month and 
no  positive result was obtained. Serologic invertigations were per- 
formed in 344 children oldcr than 1 year. Only one boy w'is HBsAg 
positive and suffered from hepatitis B. New appearance of anti-HLlc 
with increase of anti-HBs was  observed in 1 child. An increase of 
anti-HBs without revaccination was observed in 31 children. Anti- 
HBs antibodies were investigated in 290 children in the period of 3 
months after basic vaccination. Protective levels of anti-HBs anti- 
bodies were shown in 278 children (95.9%). 
Conclusions: Vaccinatioir of newborns of HbsAg-positive moth- 
ers against hepatitis B provides long-term protection in the majority 
of children. Grant support: Ministry of Health, Czech Republic 
(IGA 3520-3). 
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(p5111 Enhanced IL-10 expression as a predictive 
factor of non-responsiveness (NR) to hepatitis 
B vaccination (HBV) in uremic (U) patients: 
association with HLA configuration 
J. Stachowski, D. Runowski, C. Barth, J. Kramer, G. Fiist, W.1. 
Sulowicz, H. Rokossowski, J. Maciejewski, C.A. Baldamus. 
Department of Internal Medicine(ll.7, University o f  Cologne, Gemany; 
h'ational Inrritute o f  Hematology and lr~munology, Hungarian Academy 
qf Sciences, Budapest, Hnnpry; Department o f  Nephrology, Institute qf 
Pediatrics, University of Poznan; Department o f  Nephrology, jagiellonian 
University, Krakdw, Poland 
Objectives: Thl  lymphocytes (expression of IFN-gamma and IL-2) 
promote delayed hypersensitivity and cell-mediated cytotoxicity, 
whereas Th2 cells (IL-4 and IL-10 production) exert suppressive 
effects and induce immune tolerance. 
Methods: This study evaluated the relationship between T h l /  
Th2 activity, HbsAg processing and genetic factors (HLA class I, I1 
and 111-C4, B factor (Br) complenient allotypes) in 175 U patients 
on henioddysis immunized with HBV vaccine: 126 responders (R, 
anti-HBs 10 U/mL) and 49 non-responders (NR). Flow cytometry, 
RT-PCR and sorted CD4 T-lymphocyte cultures were used. 
Results: Increased IL-4 and 1L-10 activity was closely associated 
with NR (p<0.00001). HBsAg internalization by monocytes was 
blunted in NR (pCO.001). TCR/CD3 receptor expression in NR 
were significantly decreased as compared to the R (178*24 versus 
305257 arbitrary units, p=1.39X lo-'). TCR/CD3 receptor density 
was strongly associated (correlation coeficient=0.82, p<0.0001) 
with the stimulation index (SI) values of CD4 T-cells. Examined 
parameters were found to be under dual genetic control: (1) 
enhanced Th2 activity associated with the blunted HBsAg internal- 
ization capacity of monocytes, very low density of the TCR/CD3 
receptors and very low SI were found in N R  patients carrying HLA- 
Al, HLA-B8 and HLA-DR3 alleles; (2) TCR/CD3 expression and 
function in R were found to be significantly lower in carriers than 
in non-carriers of two MHC class I11 complement protein alleles: 
C4A*h, and B f E  
Conclusions: Acquired U factors overlapping the individual 
inmunogenetic background contribute to hepatitis B vaccination 
failure in U patients. Estimation ofThl /Th2 activity and M H C  class 
I11 alleles might have a good predictive value for suspected immune 
reactivity in U patients. 
Ip512] Activated lymphocyte markers CD3+HLA-DR+, 
CD3+CD25+ and CD3+CD122+ in patients with 
acute HBV infection 
M. Geneva, P. Pavlov. Department of Infectious Disease, Medical 
University, Plovdiv, Bn{qaria 
Objectives: The evolution and prognosis of acute hepatitis B virus 
infection and its outcome depend on the interaction between the 
virus antigens and the factors of cell-mediated immunity. The study 
included, besides the detection of virus hepatitis markers and 
biochemical analysis of blood, determinations in peripheral blood of 
relative (in X )  and absolute number (in A) of activated T-lympho- 
cytes CD3+HLA-DR+, CD3+CD25+ and CD3+CD122+. 
Materials and methods: 32 patients with proven acute HBV 
infections (21 males,ll females, age range 14-40) were placed under 
observation. The patients were examined during the acute phase of 
the disease and before leaving hospital. Immunophenotyping of the 
cells was done with Cytometry Epicx XL-MCL, Coulter, utilizing a 
selected panel of Coulter monoclonal antibodies. 
Results: The results obtained from patients, compared with 
healthy controls (n=37), show the following changes: increased 
CD3+HLA-DR+ and CD3+CD122+ (pCO.001) at the beginning 
of the disease and increased absolute numbers of CD3'HLA-DR' 
during the early recovery phase. The evolution of the results shows 
a significantly decreased percentage of CD3+HLA-DR+ (pCO.01) 
before dehospitalization. 
Conclusions: The patients with acute HBV infection have signif- 
icant increases of CD3+HLA-DR+ and CD3+CD122+. 
Prognostic importance of serum level of IL-6 in 
self-limited and fulminant acute hepatitis B 
M. Geneva, A.L. Murjeva. Department of Infectious Disease, Mediral 
University, Plovdiv, Bu[pria 
Objectives: To study the dynamic changes and prognostic value of 
IL-6 serum level in patients with acute hepatitis B virus infection. 
Materials and methods: 44 patients with acute HBV infections 
(19 males and 25 females, age range 1440) were placed under obser- 
vation. The patients were examined 2-7 days after icterus appear- 
ance, and 2 and 3 decades after that and before dehospitahzation. 33 
patients with self-limited (group 1) and 6 with fulminant (group 11) 
hepatitis were studied. ELISA (Endogen Inc., USA) was used. The 
control group included 12 healthy people with mean IL-6 values 
1.8151.30 pg/mL. 
Results: Patients from group I and I1 had significantly higher 
levels of IL-6 in comparison with the control group @<O.Ol).  Those 
with fulminant hepatitis who died had mean levels 109.14239.5 
pg/mL in the first decade after icterus appearance, but those who 
survived had levels 18.4552.10 pg/mL. The difference between 
them is significant @<O.Ol) .  
Conclusions: IL-6 serum level is significantly higher in patients 
with acute self limited and fulminant hepatitis B. Overproduction of 
IL-6 in the first decade after icterus appearance may have prognostic 
importance for the outcome of the acute hepatic failure. 
(p5141 Development of hepatic failure in the course of 
acute viral hepatitis 
V. Tzaneva, V. Philipova, N. Dimitrov. Department of Infectious 
Diseases, Thracian University, St Zagora, Bukaria 
Objectives: To analyze the epidemiologic, clinical and laboratory 
data in patients with acute hepatic failure in the course of hepatitis 
B and D. 
Materials and methods: During the period from 1993 to 1998, 
the total number of patients with viral hepatitis B and D for the Stara 
Zagora region was 1858. 13 of them developed acute hepatic failure. 
In 9 of the cases, hepatitis B viral infection was detected, and in 4, a 
superinfection with hepatitis D. 
Results: The patients' age range is from 9 months to 65 years. In 
3 cases we observed subacute progressive to lethal course of the 
disease. They were from the older age group with another underly- 
ing disease-oncologic or hematologic. Acute course of the disease 
was observed in the younger patients. Five of them showed severe 
liver damage with lethal outcome. 
Conclusions: The region has a high prevalence of hepatitis B, 
especially among some ethnic groups like gypsies. They develop 
acute hepatic failure after superinfection with hepatitis D. In the 
other cases, the disease is a result of invasive surgical intervention or 
stomatologic treatment. In spite of efforts to manage the disease, the 
case-fatality rate is high. The best approach to the prevention of 
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disease and decrease of the mortality rate is imniunoprophylaxn and 
the control of sterilization. 
1-1 Plasma fibronectin, as marker of severity of 
acute HBV infection in children 
L. Koretskaya, I? Khaikin, V Yakovenko, A. Chergiiiets. Medical 
Academy, hfections Hospitaal Dnipropetroosk, Ukraine 
Objectives: Study of plasma fibronectin (FN) level in patients with 
different severity of acute HBV infection. 
Methods: We have investigated 45 patients with acute HBV infe- 
cion. Levels of FN in plasma were measured using ELISA. Children 
were divided into two groups: group 1 with a moderate form of acute 
HBV infection (25 patients), and group 2 with a severe form (20 
patients). The level of FN in the control group (20) was 250 mg/mL. 
Results: The average concentration of FN in group 1 was 
530.0?20.0 mg/mL, and in the group 2 it was 715.7k30.0 nig/inL 
(jKO.05). The increase in FN concentration was determined in 70%) 
of patients in group 1 and in 80% in group 2. We also determined 
direct correlations between FN and ALT levels ( ~ 0 . 4 8 ,  p<0.05) in 
two groups of patients. 
Conclusions: An increase in FN concentration is probably a 
marker of severity of acute HBV infectlon. 
Prevalence of hepatitis C antibodies in a large 
sample of Belgian healthcare workers 
R. Vranckx', P. Jacques', G. Moens'. 'Institute of Public Health, 
Brrrssels, 'Uniiwsity of h u v e n ,  Belgium 
Objectives: To assess the risk for hepatitis C virus infection in 
Belgian healthcare workers (HCW). A seroprevalence study of anti- 
HCV/IgG was conducted among a systematic sample of 5068 
employees in various professional groups employed in 22 general 
hospitals in Belgium. 
Methods: The blood samples were tested using third-generation 
tests. Positwe screening results were tested by confirmation assays. 
Results: 21 H C W  were found positive for anti-HCV The over- 
all prevalence was 0.41% (95% CL: 0.24-0.59). A statistically signif- 
icant association was found with a history of blood transfusion and 
with antecedents of clinically apparent hepatitis (OR3-3.98; 95% CL: 
1.60-9.90). Although the ORs for the frequency of blood contact 
were slightly elevated, these were not significant. Moreover, a history 
of needlestick accidents showed a non-significant OR of 1.28, and 
no statistically significant difference was found between employees 
with various duties and tasks, such as nursing, catering, laboratory 
and technical duties. 
Conclusions: The findings from this large study among HCW 
suggest that (1) a history of blood transfusion and clinically apparent 
hepatitis are niost strongly associated with the presence of anti-HCV, 
and (2) HCW are not at increased risk for HCV infection, although 
occasional transmission through percutaneous injuries remains possi- 
ble. 
1-1 HCV transmission in steady heterosexual 
couples 
P. Costa, F. Alessi, M.L. Spina, G. Gattuso, B. Morandini, G. 
Perboni, A. Scalzini. It+ctioirs Diseases Departnimt, 'C. I'mm ' 
Hospital, M a ~ ~ f t i a ,  I d y  
Objectives: To estimate the risk of sexual tran\misiion of H(:V in 
steady partners of anti-HCV-positive (HCV+) subject\. 
Methods: From January 1997 to June 199X, 127 steady hetrro- 
sexual partners (P) of HCV+ index cases (C)  were cnrolled in an 
observational study. The couples had no history of drug abuse. P were 
evaluated for anti-HCV-Ah; C and HCV+ P undcrwent serum 
HCV-RNA determination, geriotyping or serotypnig, and answei-ed 
a questionnaire regarding aiiainnestic data, parenteral ritk factors and 
sexual behavior. 
Results: Of 127 C, 61 nialcs and 66 females, 114 (00%) were 
HCV-RNA+. At enrollment, 12/127 (Y.4'%1) P were HCV+; rvalu- 
ation of genotype or serotype showed no homology 111 4 couples and 
homology in 5; 3 couples are still under study. Coiiiparat~ve analyw 
of the 8/127 (6.2%) couples possibly HCV co-infected by \exu:11 
traiisniission (group A) with couples not HCV co-infected (group B) 
did not show statistically significant differences in age, length of reL- 
tionship, major surgical events, other parenteral risk factor-\, rcgular 
use of condoms, prevalence of HCV-RNA+ and genotype or 
serotype 1 in C. Length of anti-HCV-Ab positivity w a s  25.2k24.5 
months in group A versus 45.8k27.5 in group B (p=0.02, 9.5% CI); 
moreover, a history of blood transfusion before 1989 was reported in  
3/X versus 5/111 P respectively in group A and group B @ = O . O O ~ ~ ,  
CI 95%). 31 P were retested for HCV serology after d m e a n  period 
of 38.7k16.9 months and no one seroconvertcd in spite of regular 
condom use being reported by 7 couples only. 
Conclusions: The risk of sexual tranmiission of hepatiti\ C: virus 
in steady, heterosexual partners of HCV' subjccts i\ not clear and 
probably very low. 
(p5181 Distribution of HCV genotypes in viremic 
patients with 8-thalassemia 
M. Christofidou', C. Lahropoulou-Kardtza', V. Bousgouni', C; 
Dimitracopoulos' , I. Spiliopoulou' , 'Depurmierit ($ , ~ f i ~ - r ~ ~ / ~ i ~ ~ / ~ ! ~ ) ~ ,  
2L)Elfartnictit 4 Internal Medicinr, School of Medicine, t ;n iv twi ty  ,!f 
Patras, Patras, Greece 
Objectives: Hepatitis C virus (HCV) is considered t o  he the priil- 
cipal etiologic agent of post-transfusion hepatitir and is chdracterized 
by high genome heterogeneity. The a i m  of thlt study is to invc\tig:ite 
the distribution of HCV genotypes among 26 polytran\fused p:iticnt\ 
with b-thalassernia and chronic hepatitis C (CHC), to estimite the 
possibility of superinfection by different HCV genotypes a n d  to 
correlate HCV genotypes with viral load in infected patientc. 
Methods: Twenty-six sera, anti-HCV and HCV ILNA positive, 
were examined. Anti-HCV was screened by MEIA 3 (Abbott). 
Reactivity was confirmed by LIA 3 (Sorin). HCV R N A  was deter- 
mined by RTPCR (Amplicor, Roche). Genotyping was carried 
out by INNO-LiPA (Iniiogenetics), which allows clawfication 
into 6 major genotypes (1-6) and 5 subtypes (la, lh, 22, 2h, 3c). 
Viral load w3s quantified with a branched DNA m a y  (Quaiitiplcx 
2, Chiron). 
Results: Genotypes assessed in 26 patients with C H C  were: 1 
(n=9), 2 (n=5),  3 (n=4), 4 (w=3), uiideterininahle (rz=5), wbtypes 
l a  (ri=6) and l b  (n=3) and mixed infection 2 a f 2 c  (i1=2). Viral load 
was significantly higher in both of the mixed 2a+2c infectioiis, with 
a mean concentration of HCV R N A  of 20.5 Eq/mL, and a h  in 
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genotype 4, with a mean HCV RNA concentration of 19.2 Eq/mL. 
In the other cases, HCV RNA concentrations ranged from 0.2 to 3.2 
EqimL. 
Conclusions: Our results suggest that HCV genotype 1 is the 
most prevalent in 0-thalassemic patients with C H C  and in who 
viremia is relatively Iow. Subtype la  is the most frequently detected. 
Subtype lb, which has scant response to interferon therapy, was found 
only in three cases. 
Prevalence of antibodies to hepatitis C virus 
among hernodialysis patients in our hospital 
A. Gavarro, J. Hernandez, A. Veraguas, E. Berlanga, E Campos, M. 
Torra. Laboratory Service, Corporacio Sanitaria Parc Tauli, Sabadell, 
Barcelona, Spain 
Chronic liver disease represents one of the most important causes of 
morbidity and mortality among hemodialysis patients, hepatitis C 
viral infection being mainly responsible for these affections. 
Objectives and methods: The aim of this study is to evaluate 
the prevalence of hepatitis C infection (Abbott anti-HVC MEIA test 
in an AXSYM autoanalyzer, and confirmation by RIBA-I1 HCV- 
Deciscan, Pasteur) in 145 patients with chronic renal failure treated 
in the Hemodialysis Unit of our hospital. We have also studied the 
relationship between hepatitis C infection and blood transfusion 
history among these patients. 
Results: Antibodies against hepatitis C virus were detected in 24 
patients (prevalence 16.6%). Among the positive patients, half had 
received previous blood transfusion. Among the 121 patients witb- 
out virus C infection, 76 had a blood transfusion history (62.9%). 
The prevalence of virus C infection in patients without a blood trans- 
fusion history (21.1%) is greater than among those who had received 
blood transfusion (13.6%). We have studied (chi-square test) the rela- 
tionship between virus C infection and previous blood transfusion 
and we have not found significant statistical differences between the 
groups @=0.240). 
Conclusions: The prevalence obtained among our hemodialysis 
patients is similar to prevalences described in other hemodialysis 
populations. We have not found blood transfusion history as a risk 
factor of virus C infection among our hemodialysis population. 
I=] Hepatitis B virus (HBV) core particles as the 
basis for multivalent vaccines: evaluation of 
optimal insertion sites 
Authors:D. Koletzki’, A. Lundkvist2, H.  Meisel’, S .  Lachmannl, R. 
Gelderblom’, K. Brus Sjolande?, E. Nugel’, G. Borisova4, D.H. 
Kruger’, K. Ulrich‘. ‘Institute of Virolqy, Charite‘ Medical School, 
Berlin, Germany; ’Swedish Institute of Infectious Disease Control, 
Stockholm, Sueden; jRobert Koch Institute, Berlin, Germany; 
‘Biomedical Research and Study Cetrter, R i a ,  Latvia 
Objectives: Comparison ofpotential insertion sites in the HBV core 
in respect to particle formation, optimal antigenicity and immuiio- 
genic~ty of foreign peptide sequences. 
Methods: E. coli expression vectors were generated allowing the 
insertion of foreign sequences into the HBV core at different posi- 
tions (N- and C-termini, immunodominant c/el region). Two 
model sequences were used for insertion: the pentapeptide DPAFR 
from the preSl region of HBV and the 45 N-terminal amino acids 
of the nucleocapsid protein of Puurnala (PUU, Strain Vranica, 
Hallnas) hantavirus. Formation of core-like particles was estimated 
by sucrose gradient fractionation and subsequent ELISA and EM, the 
antigenicity of particles by several ELISA formats, and the immuno- 
genicity of particles (carrying the PUU insert) by immunization of 
bank voles and subsequent homologous virus challenge. 
Results: The model sequences inserted separately into the three 
different sites all allowed the formation of core-like particles; the 
c ie l  insertion site was found to be the preferable site for their 
surface exposure. The highest PUU-specific antibody response and 
an at least partially protective potential (2 out of 4 and 2 out of 5, 
respectively) was observed in bank voles immunized with the N- 
and c/el constructs. In contrast, core particles carrying the same 
amino acids, but from a different PUU strain (CG18-20), at their 
c ie l  site protected 4 out of 5 animals completely against a subse- 
quent virus challenge. The C-terminal constructs did not induce 
any protection. 
Conclusions: The HBV core tolerates the insertion of short and 
medium-sized sequences at the N- and C-termini and the c ie l  
region. The c ie l  insertion site presented the insert on the surface of 
core-like particles, resulting in high antigenicity, iminunogenicity 
and protectivity of the inserted sequence. 
w1 Markers of hepatitis B virus and hepatitis C 
virus infections in children with HIV/AIDS from 
a nursing-care home 
L. Lancu’, S. Sfartz’, FI. Zugun’, E. Negut’, M. Balteanu’. 
‘Urriversity of Medicine and Pharmacy ‘Gr. 7: Pupa’, Lasi, “Gulliver’ 
Children House, Lasi, -’ ‘Cantanrzino’ Institute, Bucharest, Romania 
Objectives: To investigate the prevalence of hepatitis B virus (HBV) 
and hepatitis C virus (HCV) markers in children with HIViAIDS 
from a nursing-care home in Lasi, Romania. 
Methods: The study group consisted of 47 children (25 male and 
18 female) with an average age of 8.3 years (range 6.9-9.1 years). 
AIDS stage was established according to CDC Atlanta criteria (1993). 
HBV markers (HBsAg, anti-HBcItotal antibody-Ab, HBeAg, anti- 
Hbe Ab) and anti-HCV Ah were determined by ELISA (Murex). 
Anti-HIV Ah was determined by ELISA and Western blot. CD4 
count and transaminase levels were also determined. 
Results: O f  47 children tested, 27 (57.8%) were positive for 
HBsAg and 29/32 (90.6%) for anti-HBc/total Ah. Two of them had 
anti-HBe Ab (4.1%), 50% (11122) were positive for HBeAg and 
40.9% (9122) were positive for both markers. One child presented a 
typical serologic profile for HBV2 (HBsAg and HBeAg positive and 
negative for anti-HBc/total Ah). Four children (8.5%) were positive 
for anti-HCV Ab. The CD4 count was under 200imm’ for 11 chil- 
dren (23.4%) and there were modiked transaminase levels in 10 of 
them (21.2%). 
Conclusions: (1) Compared to HBsAg in our healthy population 
(10.8%) of the same age group, the prevalence of HBsAg was signif- 
icantly higher (57.8%) in HIV-infected children @<0.001). (2) In 
our closed units, HBV infection can be considered nosocomial as well 
as HIV infection but not HCV infection (8.5% versus 16.5% from 
units of the same type). 
[p522] Interferon-alpha plus ribavirin retreatment in 
patients with chronic hepatitis C 
G. Cariti, M. Depaoli, A. Gramoni, D. Pini, P. Gioannini. 
Department of Medicine and Suqical School, Division o f  Infctious 
Disease, University u j  Ttrrin, Italy 
Objectives: Retreatment with interferon alone has in non-respon- 
ders (NR) and in relapsers (RE) to a previous 1FN therapy a very 
poor eEect. We have investigated the response to the combination 
therapy IFN-alpha plus ribavirin in both these groups. 
A b s t r a c t s  
Before treatment End of treatineni 24 wks follow-up 
I t  RE 811 I CR (72.7 %) 711 I SR (63.6 %) 
223 
, 9  NR 419 CR (44.4 %) 219 SR (22.2%) 
m] Response to natural leukocyte alpha-interferon 
(alpha-IF) in chronic hepatitis C (HCV-CAH) 
patients: comparison between two different 
regimens 
G. Cariti, D. Phi ,  A. Granioni, M. Depaoli, R. Gioannini. 
Departnicnr gf Mdicinr mid Suyirat Scfiool, Division of I+rtiorrs 
Discasc, Ilniversity o j  Xrrin, Italy 
Objectives: To assess the effectiveness of natural leukocyte alpha-IF 
therapy in HCV-CAH patients. 
Methods: 63 patients were studied for 18 months. Inclusion critr- 
ria were based on histologically confirmed HCV-CAH altered levels 
of aiiiiiiotransferases and detectable HCV-RNA in serum; all patients 
were relapsers (KE) or non-responders (NR) to 6-month therapy 
with recombinant or lyniphoblastoid alpha-IF. Patients were assigned 
to two groups. Group 1: 42 patients (23 N R  and 19 RE) were treated 
with natural leukocyte alpha-IF 6 M U  thrice weekly for 6 months. 
Group 2: 21 patients (7 N R  and 14 RE) were treated with natural 
leukocyte alpha-IF 6 MU thrice weekly for 12 months. 
Results: Group 1: at follow-up, 12 months after treatment, HCV- 
RNA was cleared from serum in 19 of 42 (45%1) patients, that is, 9 
of 19 R E  and 2 of 23 NR. Group 2: 6 months after treatment, serum 
HCV-RNA was undetectable in 8 of 21 patients (38%1); this responw 
was achicved in 6 of 14 R E  and 2 of 7 N R  patients. 
Conclusions: Natural leukocyte alpha-IF is effective in the ther- 
apy of HCV-CAH patients. A 12-month course of therapy does not 
appear to be inore effective than a (,-month one in RE patients but 
is inore effective in N R  ones (28.6% versus 8.7%). 
Immunologic and metabolic effects in patients 
with chronic hepatitis C 
M. Uotsenko, E. Dotsenko. Vitehsk Stare Medical bistitntc, Vitdrk, 
Rrpirhlir of Belanrs 
Objectives: To study the immunologic and metabolic effects in 
Results: The low levels of cholesterol HDL were found in patients 
with chronic hepatitis C. These are two times lower than the corre- 
sponding levels in patients with chronic hepatitis B (0.6320.1 1 
mM/L versns 1.1620.1 mM/L, respectively). Hypo-alpha- 
lipoproteineniia is the niost important feature for chronic hepatitis C. 
We found higher levels of total IgE in patients with chronic hepati- 
tis C (579k157.7 IU/niL compared with corresponding levels in 
patients with chi-onic hepatitis I3 (244256.0 IU/niL). 
Conclusions: Chronic hepatitis C is a risk fx tor  for the devel- 
opment of atherosclerosis. The high levels of IgE are possibly related 
to chronic inflammation. 
A new biological activity of NS3 of HCV 
R. Kuhl ' ,  J. Schulze zur Wiesch', R. Laufs', M. Heiland', I? 
Dorowski'. 'Iristifur Firr Medirinisciie &fikrohioio,cjc und Iimirtnolqic, 
Uriiver.citufsklinik Eppendo$ 'Nordtuestdeutsclie Ki+rklinik, Mund-, 
Kid&, (;c~sirlitsrliiru~ie, Universifdtskliviik Eppciidorj -'Bernlrard-~~~~rlzt- 
Inslitutfirr Eopcrimedizin, Abt. Virolqie, Hamlyy, Gcrrrrany 
Objectives: Previously, we have denionstrated that the full-length 
non-structural protein 3 of HCV (NS3) and its N- and C-tcriiiinal 
truncated forni (tNS3) associate to forni stable complexes with core 
histones H2B and H4.The changes in the properties of histoncs a s  
substrates for CAMP-dependent protein kinase (PKA) and protein 
kinase C (PKC) were found to be a direct consequence of the intcr- 
action. In the present study we localize the histone-binding domain 
of NS3 and investigate the mechanisms by which NS3 affects the 
functions of the histones in vitro. 
Methods: HCV protein exhibiting the mentioned histone- 
binding activity was produced in a bacterial expression system and 
purified, and the binding to histones was biocheiiiically charactcr- 
ized. The region of NS3 involved in the interaction with histones 
was defined by proteolytic fragmentation, microsequencing and a 
histone-binding assay. Furthermore, a test to quantify the interaction 
of histones with DNA was established and the binding of DNA to 
histone as a function ofNS3 concentration was analyzed with graph- 
ical methods. 
Results: The investigated fragment of HCV polyprotein consist- 
ing of amino acid residues 1189-525 displayed significant histone- 
binding activity. The binding occurred at niolar ratio 1:1 of histone 
to tNS3 and was mediated by a linear stretch of amino acids located 
between residues 1343 and 1379 of the tNS3. To deinonstrate that 
tNS3 affects the binding of DNA to histones we used two indepen- 
dent methods: overlay assay and binding assay oii sepharose beads. 
Graphical analysis of the binding kinetics revealed an uncompetitive 
type of inhibition. 
Conclusions: Our results provide the first evidence that NS3 
binds and affects the functions of core histones. The mechanism by 
which the NS3 interferes with the histone functions involves confix- 
iiiational changes of the histone inolecule. 
lp5261 Decline in prevalence and incidence of 
hepatitis C in hemodialysis patients (HD) 
patients with hepatitis C. 
Methods: In our work we used the methods for determination 
of total 1gE (Serono, Italy), methods for deterniiiiation of lyinpho- 
cytes bearing receptor to IL-2, and enzymatic methods for determi- 
nation of total cholesterol, cholesterol HDL and cholesterol LDL 
K .  Watschinger', C. Luger', E. Leitiler', C. Jebelean', L. Binder', 
M. Haditsch', H.C. Stummvoll', H.  Mitterinayer'. 'Dcyartrmzt of 
Mcdiral MicrobioloAy urzd Hyfiicrie, 'Dcparfrwrt gf Irrtertial Mcdirii ie 111, 
Elisabcrhirieri Hospifal, Lim,  Auwm 
(Corniay, Diana, Switzerland). We have studied blood saniples from 
64 patients with chronic hepatitis C and from 213 patients with 
chronic hepatitis B. 
Patients on renal replacement therapy have a higher prevalence of 
HCV infection as conipared to the general population. To analyze 
trends in the prevalence and iiicidencc of HCV infection in  our dial- 
2 2 4  Cl in ica l  M i c r o b i o l o g y  and In fec t ion ,  Vo lume 5 Supp lement  3 
ysis unit, all HD patients were screened annually for HCV infection 
starting in 1994. 
Materials and methods: Screening methods included HCV 
antibody (AB) testing plus a confirmatory assay in positive sera. 
Testing was performed by a second-generation ELISA (HCV EIA, 
Abbott) plus Abbott supplementary assay in 1994, by a third- 
generation ELISA (HCV EIA, Abbott) plus Matrix test (Abbott) in 
1995, 1996 and 1997, atid by the Abbott AxSym HCV Version 3.0 
plus Matrix test in 1998. Screening for HCV RNA was done with 
a commercially available PCR kit (Amplicor, Roche). HCV infec- 
tion was determined by positive HCV antibodies, HCV RNA detec- 
tion or both. 
Results: No, ofparients A B  pos. R N A  pos. No. o f  H C V  Inf: 1994 
156 25 16 25 (16.0%) 1995 149 27 20 27 (18.1%) 1996 177 30 22 
(2XAB neg.) 32 (18.0%) 1997 140 23 15 (2XAB neg.) 25 (17.9%) 
1998 151 14 12 14 (9.3%) 
There was a significant decline in the prevalence and incidence of 
HCV infections in our dialysis unit. The incidence of HCV infec- 
tion dropped from 2% in 1995-96 to 0% in 1997-98. This decline 
was due to the reduced number of HCV infections in patients start- 
ing with HD and to the lack of de novo HCV infection in patients 
already on HD. 
Conclusions: The increasing awareness of blood-borne infections 
and the decreased use of blood products in HD patients, isolation of 
patients and the use of dedicated machines could have an impact on 
the declining number of HCV infections. 
[=I Vaginal shedding of hepatitis C virus 
R. Albuquerque, T. Veneno, E. Prieto, R. Castro, V. Carnall, 
W.F.C. Ferreira, E Exposto. Departamento Microbiologia, Faruldade 
Cirncias Medicas, UNL, Unidade Virologia, Irzstituto Higiene Medicina 
Tlopical, UNL,  Unidade Doencas Sexualmente Eammitidas, Institnto 
Hkiene Medicina Tropical, UNL , Lisboa, Portugal 
A group of 14 female prisoners found to be infected with hepatitis 
C virus (HCV), enrolled in a sexually transmitted diseases study, were 
evaluated for the vaginal shedding of HCV. Blood, from which 
plasma and peripheral blood mononuclear cells (PBMC) was 
obtained, and a vaginal wash with 5 mL of RPMI medium was 
performed. The latter was centrifuged and the pellet separated. The 
supernatant was also centrifuged at 30 000 rev/min for 3 h. HCV- 
RNA was extracted &om 200 mL of plasnia, 3 million PBMC, the 
pellet of the vaginal wash and the pellet of the supernatant, reverse 
transcribed, amplified and typed using primers from the core region. 
The mean age of the studied population was 30.2 years. HCV-RNA- 
positive results obtained were: plasma 100% (14), PBMC 64.3% (9), 
vaginal pellet 42.5% (5) and supernatant of vaginal wash 42.8% (5). 
The presence of HCV-RNA in vaginal secretions, either vaginal cells 
or supernatant, was detected in 7 out of 14 (50%). In 3 (21.4%) a 
positive result was found in every analyzed product. The HCV geno- 
types which were identified in plasma (la 35.7%, lb  35.7%. 3a 13.3% 
and lbf3a 14.3%) matched with those in PBMC and vaginal wash 
in all cases except in the mixed infections. In these, genotype 1 b was 
only detected in plasma. 
jp5281 HCV genotypes in Polish children with chronic 
hepatitis treated in Children Memorial Health 
Institute 
A. Fangrat, K. Dzierzanowska, H.  Jaworska, M. Woynarowski, K. 
Madalinski. Children Memorial Health Inst., Dept. of Clinical 
I m m u n o l o ~ ,  Warsaw, Poland 
Objectives: To estimate viral genotypes in Polish children with 
chronic hepatitis C and to compare them with a genotype pattern in 
adults. 
Methods: HCV infection in 65 children (aged 5-18 years) from 
various regions of our country was confirmed by antibody testing 
(Abbott IMX 3.0) and RNA detection by RT-nested PCR with 
primers derived from 5UTR of the viral genome as described else- 
where. All samples were tested twice with reproducible results. 
Negative and positive controls (Pelipsy HCV-RNA, CLB) were 
included in each assay Genotyping was performed with cDNA from 
PCR-positive samples by use of Inno-Lipa (Innogenetics). 
Results: Thirty-five of 65 (54%) HCV-positive children appeared 
to have subtype lb, 24 (37%) subtype l a ,  3 (4.6%) subtype 3a, 2 (3%) 
type 4 and only one (less than 2%) mixed genotypes lb/3a. After 6 
months of IFN treatment of the child with mixed infection, only one 
subtype (lb) was detectable. As described previously in adults with 
chronic hepatitis C in Poland, subtype l b  was also identified most 
frequently (75%), whereas 1 b seemed to be very rare (not more than 
5%). 
Conclusions: Genotype l b  appeared to be the most prevalent 
subtype in children with chronic hepatitis C treated in our hospital 
but the genotype pattern in chiidren might he different from that in 
adults. 
(p5291 Therapeutic efficacy of interferon + ribavirin 
(IFN + RI. 6 versus 12 months, in chronic 
hepatitis C (CH-C) patients who were non- 
responders (NR) or reiapsers (RR) to a previous 
treatment with interferon 
J. Cordoba, V Olaso, B. Lopez, B. Lainez, J.J. Urquijo, J.M. 
Molina, M. Prieto, M. Gobernado, La Fe Hospital, Microbiology, 
klencia, Spain 
Objectives: To determine, in a prospective, randomized study, the 
sustained biochemical and virologic response rate (SBR, SVR) to 
treatment with IFN+R for 6 and 12 months, and the adverse effects. 
Methods: Evaluation was made of 110 patients with CH-C 
(HCV-RNA positive) treated with IFN (3 MU/3 times a week) and 
R (1200 mg/day); the patients were subdivided into two groups: (A) 
6 months (RR 22; NR 32); (B) 12 months (RR 28; NR 28). The 
mean follow-up (F) waq 12 months. ALT, Hct, Hb, leukocyte and 
platelet count, genotype (LiPA), viral load @DNA-2.0) and 
Knodell's I. were determined at baseline. HCV-RNA was deter- 
mined at the end of treatment (ET) and of E 
Results: The baseline characteristics of the two groups were simi- 
lar, except for age, which was lower in group A. The drop in Hct 
(p=0.00001) and Hb (p=0.0001) during treatment was similar in 
both groups. The BR and V R  rates at ET and EF were similar when 
comparing the RR and N R  in both groups (EF, group A, R R  46.7% 
and 33.3%, N R  8% and 8%. group B, R R  64.3% and 64.3%, N R  
6.2% and 0%, respectively). SVR was found in 48.3% of the RR 
patients (group A 5/15; group B 9/14) and in 4.9% of the NR 
patients (group A 2/25; group B 0/16). The SVR rate was similar 
when comparing the genotype (la 33.3%; l b  19.6%; others 50%). 
Conclusions: The combined treatment is effective in RR 
patients with genotype 1, although the efficacy and the adverse effects 
A b s t r a c t s  225 
do not increase with greater treatment duration. The SBR overesti- 
mates the response rate. 
IP530] Factors predictive of non-response to 
treatment with interferon + ribavirin (IFN + R) 
in patients with chronic hepatitis C (CH-C) 
J. Cordoba, V Olaso, B. Lopez, J.M. Molina, B. Lainez, J. Jaen, M. 
Siles, M. Pastor, M. Gobernado. La Fe Hospital, MicrobioloD, 
Valewcia, Spain 
Objectives: To determine factors predictive of non-response to 
treatment with IFN+R in patients who were non-responders (NR) 
or relapsers (RR) in a previous cycle of treatment with IFN. 
Methods: A total of 70 patients with CH-C treated with IFN 
(3 MU/ 3 times a week) and R (1200 mg/day) for 6 or 12 months 
were included ( N R  41; RR 29). The mean follow-up was 12 
months. ALT, ferritin, genotype (LiPA), viral load (bDNA) and the 
histologic lesion (HL) were determined at baseline. HCV-RNA was 
determined at the 1st and 3rd months of treatment and at the end of 
follow-up. The predictive values (PV) of the baseline characteristics 
were determined by analysis of the R O C  curves, and the relation- 
ship and independent prognosis using univariate and logistical regres- 
sion analysis. 
Results: The sustained response rate (SR) was 20%. Age (<43), 
serum ferritin (<221), grade (<7) and stage (11) of the HL, and 
viral load (18.9) revealed an area under the ROC curve of 0.5, and 
were simihr when compared among themselves. The negative PV of 
these variables was 76-loo%, with a positive PV of 25-34%. Age, a 
history of transfusiom, ferritin levels and HL grade and stage were 
related to N R .  No baseline variable showed an independent prog- 
nostic association with response. The positive PVs of HCV-RNA at 
1 and 3 months were 95% and 100%, whereas the negative PVs were 
68% and 65%, respectively. These PVs were similar to those demon- 
strated for ALT. 
Conclusions: Age (43), ferritin (221) and HL grade (7) and stage 
(1) are better predictors of N R  than SR to combined treatment in 
patients with genotype 1. N o  variable demonstrated an independent 
prognostic association with response. The detection of HCV-KNA 
or elevated ALT at the 3rd month of treatment effectively predict an 
absence of response. 
m] Hepatitis C virus serotypes in chronic dialysis 
patients 
K. Midilli', S. Ergin', B. Ulgen', M. Bili?, M.R. Altiparmak', N. 
Sahin', R. biztiirk'. '.VicrobioloSy Department .f Cerrahpasa School .f 
Mediririr, 'Internal Medicirie Department .f Cerrahpasa School of 
Medicine, KMC Istanbul, Turkey 
Objectives: To determine the HCV serotypes in chronic dialysis 
patients infected with hepatitis C. 
Methods: HCV serotypes were investigated in a total 35 chronic 
dialysis patients with hepatitis C confirmed by RIBA and/or RT- 
PCR. In 24 of the patients, HCV KNA was found positive by nested 
RT-PCR, and in 11 patients HCV R N A  was negative. In the latter 
group hepatitis C was confirmed by RIBA. HCV serotypes were 
investigated with a commercial EIA kit (Murex, UK). 
Results: The distribution of the serotypes is shown in the table 
below: 
HCV RNA (+) 
HCV RNA (-) 
n=24 
o=ll 
Totsl(o=35) 26 I 2 1 2 1 2 
Conclusions: The most prevalent HCV cerotypc was typc 1 in 
both patient groups (75%). Also in previous studies performed in 
various patient populations in Istanbul, serotype 1 was also the most 
prevalent terotype. Only 3 patients harbored inore than one  serotype. 
Although chronic dialysis patients comprise an epidemiologically 
distinct group, the distribution and con~position of serotypes was not 
different from the profiles observed in our region and the east 
European countries. 
lp5321 Interactions of cellular immune effector 
function, iron metabolism and disease activity 
in patients with chronic hepatitis C virus (HCV) 
infection 
G. Weiss, F. Umlaufi, M. Urbanek, M. Herold, VK. Gordeuk, 
University Hospital, Dept. of Internal Medirirzc, I t~ t rsbr i i rk ,  A trstvin 
Iron modulates T-helper cell type-1 (Th1)-mediated ininnine niech- 
anisms in vitro by downregpdating IFN-gamma activity towardc 
macrophages. To investigate the relative erects of macrophage activ- 
ity, Thl /Th2 responses, and iron status on the activity of hepatitic C. 
virus (HCV) infection and development of cirrhosis, we studied 5.5 
patients suffering from HCV-related liver disease and 28 patient5 with 
non-infectious liver disease. Serum iron concentrations, transferrm 
saturation (TB) and ferritin levels were significantly higher in HCV 
patients with cirrhosis than in non-cirrhotic HCV patients (p<0.05) 
but these differences were not observed when comparing cirrhotic 
with non-cirrhotic controls. Regardless of the HCV status, the 
macrophage activation marker soluble tumor necrosis Factor receptor 
type I1 (sTNFrec75) was significantly higher in cirrhotic than in non- 
cirrhotic patients (p=0.0005), while the T h l  marker neopterin and 
the Th2 markers IL-4 and IL-10 were not significantly different. 
Moreover, sTNFrec75 levels and TB were tignificantly relatcd to 
liver damage as indicated by their positive relationship with AST 
(p<0.001 for sTNFrec75 and p=0.028 for T6)  and ALT levelc 
@=0.003 for sTNFrec75, and p=0.039 for TR)  in HCV-positive 
patients. T B  and sTNFrec75 were not significantly related to each 
other, while a positive correlation was found between IL-4 and T R  
Our data suggest (1) that activity of liver disease and iii~crophage 
activation may be causally related to each other, pointing to the possi- 
ble use of sTNFrec75 as a surrogate marker for disease activity and 
estimation of the presence of cirrhosis, and (2) that incrcased iron 
levels are not only related to liver damage but also direct the immune 
responte in HCV patients to a prominent Th2 pattern which may be 
detrimental by impairment of Thl-mediated host response mecho- 
nisnis towards viral pathogens. 
(p=0.011). 
(p5331 The prevalence of anti-hepatitis E virus IgG 
antibodies in the students of a secondary 
school in Istanbul 
S. Ergin, K. Midilli, R. Ozturk, K. Altas. MicrubioLyy Dqwtnient qf 
Cerraiipasa Scliiwl .f Medicine, KA4c Istatibd, Turkey 
Objectives: Hepatitis E virus (HEV) ic a fecal-orally trmsnntted 
virus usually acquired during the second decade of life in developing 
countries. HEV causes water-borne outbreak$ in undcrdeveloped 
2 2 6  C l i n i c a l  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  V o l u m e  5 S u p p l e m e n t  3 
and developing countries, whereas it is sporadic in the developed 
countries. The antibodies against HEV persist for 1-4 years. In our 
country the highest prevalences were reported in young adults and 
adults from the southeastern region. The purpose of this study was 
to determine the seroprevalence of HEV in preadolescents in our 
region. 
Methods: 186 students (95 females and 91 males) attending a 
secondary school in Istanbul were screened for anti-HEV IgG anti- 
bodies by EIA (Giuliana Cremascoli Chemical, Italy). 
Results: Five of 90 (5.55%) girls and 5 of 91 (S.49%) boys were 
found positive for anti-HEV IgG. The overall prevalence was 5.37%. 
Conclusions: Our results on the seroprevalence of HEV in our 
region are s i d a r  to those of developed countries, although higher 
rates were reported from other regions of our country. 
(p534] Detection of hepatitis E virus RNA in diverse 
environmental water samples collected from 
different areas of Turkey 
S. Ergin, K. Midilli, A. Ozkaya, R. Oztiirk, K. Altas. Microbiology 
Department of Cerraphara School .f Medicine, KMT: Istanbul, Turkey 
Objectives: Viral hepatitis is a major health problem worldwide, 
especially in developing and underdeveloped countries. Hepatitis E 
virus causes epidemics in areas where water sanitation is poor. 
Previous stumes performed in Turkey showed, that HEV infection 
may encountered as small outbreaks. We screened water samples 
collected from different regions soon after rainfalls for HEV RNA. 
Methods: 150 water samples were screened by RT-PCR for HEV 
RNA. Positive samples were confirmed by the dot-blot method. 
Results: Only three out of 150 samples were found positive for 
HEV RNA, two of which were obtained &on1 the same region 
(Istanbul). The other sample was obtained from the eastern Black Sea 
region. 
Conclusions: Our  results show that the occurrence of HEV in 
environniental water samples in Turkey is low, which is consistent 
with the low HEV seroprevalence indicated by previous studies and 
occurrence of the diseases as outbreaks. 
(p535j Presence of HEV in Spain: prevalence in the 
Spanish population versus immigrants from 
underdeveloped countries 
D. Tarrago', C. Turrientes', E. Lasa', R. Lopez-V&lez', M.L. 
Mateosl, E Baquero'. 'Microbiology Department, 'Hematology 
Department, Ram& y Cajal Horpiral, Madrid, Spain 
Hepatitis E virus (HEV) is a major cause of acute epidemic hepatitis 
in underdeveloped nations, but sporadic cases have been reported in 
western European countries. 
Objectives: To investigate the prevalence of anti-HEV antibod- 
ies (exposure to HEV) in the Spanish population and in immigrants 
from underdeveloped countries. 
Methods: Sera boom 863 blood donors from the Madrid area and 
sera from 91 immigrants (most of them from sub-Saharan Africa) 
who attended our Tropical Diseases Unit were investigated for the 
presence of anti-HEV IgG using a commercial ELISA (Abbott HEV 
EIA). Repeatedly reactive results were confirmed by Western blot 
assay and tested for anti-HEV IgM (HEV IgM ELISA, Genelab 
Diagnostics), 
Results: 34 (3.9%) serum samples from blood donors and 5 (5.5%) 
from immigrants were positive by anti-HEV IgG assay. The presence 
of IgG antibodies was confirmed in 25/34 blood donors and 5/S 
immigrants by Western blot. Absence of clinical manifestations of 
hepatitis, anti-HEV IgM and non-increased ALT values were 
common features of all positive-serum individuals. 
Conclusions: (1 .)The prevalence of HEV in the Spanish popu- 
lation was similar to those found in other western European coun- 
tries (2.8%). N o  risk factors for HEV transmission were found among 
positive anti-HEV IgG blood donors. (2) Immigrants under study 
(most of them from sub-Saharan countries) have a prevalence of 
5.5%. (3) Comparison ofprevalences and sizes ofboth groups (immi- 
grants and healthy Spanish population) suggests that there are other 
sources ofHEV infection apart from immigrants coming from under- 
developed countries. 
1-1 Hepatitis G virus infection in transfused 
children 
D. Tarragb', M.L. Mateos', A. Calvo', C. Camarero', A. Martin' 
'Microbiology Department, 'Pediatric Department, Ramdn y Cqjal 
Hospital, 'Boehritzger Manizheim', Madrid, Spain 
HGV is a positive-stranded R N A  virus that belongs to the 
Flaviviridae family. Since it 1s parenterally transmitted, blood recipi- 
ents are a group at risk for HGV infection. Some studies have been 
carried out in adults, but to our knowledge there are no data regard- 
ing this issue in pediatric patients undergoing transfusion. 
Objectives: To analyze the prevalence and clinical manifestations 
of HGV in children transfused during heart surgery or in the course 
of oncologic diseases. 
Patients and methods: From November 1997 to July 1998,106 
children (53 males, 53 females) were studied. Forty serum samples 
from 40 children who had undergone head surgery and attended the 
Cardiac Surgery Department for follow-up and 66 children attend- 
ing the Pediatric Department for oncologic diseases were obtained. 
Ages ranged from 1 month to 16 years. HGV R N A  and antikE2 anti- 
bodies were detected with commercially available tests (Boehringer 
Mannheim, Mannheim, Germany). 
Results: HGV RNA was detected in six children (5.8%) and anti- 
E2 antibodies were present in three (2.8%) Considering the presence 
of anti-E2 or detection of HGV R N A  as serologic markers of past 
or present infection, the prevalence was 8.7%. N o  post-transfusion 
hepatitis was recorded in the nine HGV-infected patients. None of 
them had elevated alanine aniinotransferase levels or clinical mani- 
festations of hepatitis. 
Conclusions: (1) Blood-recipient children constitute a risk group 
for HGV infection. (2) The presence of HGV RNA in serum does 
not correlate with elevated ALT level5 and HGV infection may be 
subclinical. (3) Infection resolves spontaneously in some patients. 
w) Hepatitis G virus, hepatitis B virus and 
hepatitis C virus infection in Spanish 
prostitutes 
M. de Frutos, B. Hernandez, M. Sainz, C. Navarro, P. Ruiz, €? 
Alonso, J.M. Eiros, A. Ordutia, A. Rodriguez-Torres, Hospital 
Universitario, Microbiologia, Wlldolid, Spain 
Objectives: Hepatitis G virus (HGV) has been identified as an infec- 
tious agent for humans, although its potential involvement as a path- 
ogenic virus is still controversial. In this study we have examined the 
prevalence of HGV Ab and HGV-RNA in the serum of prostitutes 
in Spain and other serologic markers of the related viruses, including 
HCV and HBV. 
Methods: Serum samples were obtained from 50 prostitutes in 
1998. HGV-RNA was measured by reverse transcriptase (RT) using 
primer sets for the 5'ntr region of the HGV genome (LCR Abbott 
A b s t r a c t s  2 2 7  
Lab, North Chicago. Ill). HGV antibody was measured by enzymc- 
linked immunosorbent assay (ELISA) using recombinant E2 protein 
(Hoehringer Manheim). HCV antibodies were detected with an 
automated detection system (ELISA, Abbott Lab, North Chicago, 
111). HCV-RNA was measured by reverse transcriptase-polymerase 
chain reaction (KT-PCR, Cobas-Amplicor, Roche). Cenotyping 
was undertaken with a reverse hybridization test of the aniplification 
obtained by RT-PCR (Innogenetics, Belgium). Serologic markers of 
HBV investigated were HBsAg and HBcAb (Abbott Lab, North 
Chicago, Ill). 
Results: The mean age was 27 years (range 18-47) and 24 (48%) 
were intravenous drug users (IVDUs). Of the 50 women, 34 (68%) 
were HCV Ah potitives and 24 (48%) were HGV Ab positives. 21 of 
the 24 with HGV Ab were also HCV Ab positive. HGV viremia was 
present in 20% of the total samples, and HCV viremia was found in 
48%. The HCV genotypes most frequently observed were la  (25%) 
and 3 (25%). Five prostitutes (10%) were co-infected with HGV and 
HCV, all of them IVDUs. Only two were HBsAg carriers, and 27 
(%%I) had positive HBcAb. 
)p5381 Acute non-A-E hepatitis in Turkey and the role 
of l T V  and other viruses 
E Tabak’, A. Mert’, S. Ergin’, R. Uztiirk’, S. Tiirkoglu2, S. 
Badur’, H. Sentiirk’, Y. Aktuglu. ’Department of Clinical Baderiology 
arid Ir!fr.itiotrs Disemcs, Cerralipasa Medical Faculty, ‘Department of 
Ciiriiral Microbiolojy arid Microbioloxy, Israanbul Medical Faculty, Istatzbrrl 
I Iniversity, Istanbul, 7irrkey 
Objectives: To determine the causes of acute viral hepatitis (AVH) 
in Turkey and to assess the relative iniportance of TTV (transfusion- 
transmitted virus) in patients with AVH who are seronegative for 
hepatitis A-E, CMV, EBV and parvovirus B19 Infections. 
Methods: We selected patients with AVH who had acute disease 
during January 1996 to October 1998. Their mean age was 24 (range: 
11-74) and 71 were male. Of the 109 cases of AVH, 88% were due 
to one of the four recognized hepatitis viruses (A-D). Proportions of 
HAV, HUV, HCV and HDV were 38.4%, 49.5’%, 2.7% and 0.9%, 
respectively. The sera of 8 patients of 13 seronegative patients were 
tested by ELISA for IgM to EBV, CMV, parvovirus 819  and HEV; 
by PCR for HBV-DNA, HCV-RNA and HEV-RNA; and by nested 
PCR for TTV-DNA. All patients were negative for TTV and other 
viruses. Thirteen patients without diagnosis denied alcohol intake, 
the use of hepatotoxic drugs and blood transfusion. 
Results: TTV is not an etiologic agent of non-A-E hepatitis in 
Turkey 
Conclusions: Approximately 12% of the AVH cases have un- 
known etiology in Turkey. One or more additional agents may be 
responsible for AVH. Therefore, efforts must be directed to search 
for new hepatitis viruseq. 
HIV-virology and treatment 
(p5391 Do time since HIV infection, basal CD4 count 
and viral load influence response to HAART? 
J.M. Guardiola, P. Doniingo, J. Ris, M. Gurgui, J. Cadafalch, M.A. 
Sambeat, J. Lbpez-Contreras, J. Barrio, G.Vizquez. Infernal 
Medicine, Hospital Sant Pau, Barcelom, Spain 
We studied the influence of time since HIV infection, bacal CD4 
count and viral load on the immunologic and virologic response of 
an unselected cohort of patients with HAART after 18 months of 
treatment. We included those patients who had started antiretroviral 
treatment with AZT (or D4T) plus 3TC plus IDV between 
November 1996 and March 1997. All patients were PI naive. Patients 
were divided into groups according to basal CD4 count (<SO, 
51-100, 101-200, 201-500 and >500/iilnl’) and viral load 
(>1 000 000, 500 000-999 999, 100 000-499 999, 50 000-99 999, 
10 000-49 999 copies/inL) and time since HIV infection 
(> 10.9-10.7-8,s-6,3-4, <3 years). 140 patients were analyzed. 
Average age was 38.4k9.7years (21-74). 103 (74%) were men. 
Mean time since HIV infection was 6.224.0 years (1-13). B a d  viral 
load and CD4 count were 495 61021 359 309 copies/niL 
(0-11 000 000) and 212t184/min3 (3-1093). Mean viral load 
decrease after treatment and CU4 count impi-oveiiicnt were 
469 968k  1 380 749 copies/niL and 172~164/iiini”. When coinpar- 
ing different basal CD4 count groups, no statistically significant 
differences were found ( ~ ~ 0 . 2 )  for the virologic response but they 
were for immunologic response (p=0.0009). When comparing basal 
viral load groups, statistically significant differeiicer were found for 
the virologic response (p=O.0001) but not for the iiiiinunologic 
response ( p 0 . 9 ) .  Considering time from HlV infection, no sigiiifi- 
cant differences were found for either virologic or immunologic 
response. 
Conclusions: In our series, basal CD4 count influenced 
immunologic response, and basal viral load influenced virologic 
response. Time since infection did not affect either parameter 
(p5401 Eighteen-month follow-up of a population of 
HIV-infected patients in HAART: daily clinical 
praxis 
M. Guardiola, E Montero, M. Barcelo, T? l)oiningo, J. Ris, M. 
Gurgui, M.A. Sambeat, J. L6pez-Contreras, G. Vizquez. Internal 
Medicine, Hosprtal Smt pau, Barcelona, S p i n  
We studied the immunologic, virologic and clmical response of an 
unselected cohort ofpatients with HAART after 18 months of treat- 
ment. Patients were included provided that they had begun triple 
antirrtroviral treatment with AZT (or D4T) plus 3TC plus Il’IV 
between November 1996 and March 1997. All patients were PI 
naive. 140 of 160 (87.5%) patients were analyzed. Average age was 
38.459.7yrars (21-74). 103 (74%) were men. Mean tiine since HIV 
infection was 6.2k4.0 years. Mean duration of prior antiretroviral 
treatment was 32.3f9.1 months (0-34). 25 (18%) were naive. Basal 
viral load and CD4 count were 495 610+-1 359 309 copies/mL 
(0-1 1 000 000) and 212f 184/1iini’ (3-1093). Mean viral load 
decrease after treatment and CD4 count improvement were 
469 968k1 380 749 copies/mL and 172-t1h4/nim3. 88 (63%) 
patients had undetectable viral load. 41 (29%) needed a change in 
treatment after an average o f 8 2 4  months (1-17). IDV was changed 
in 65% of cases. 21% needed a change in the whole treatnir‘nt. 
Treatment was changed due to secondary effects (SE) in 62% and due 
to therapeutic failure in 38%. Main SEs were: nephrolithiasis in 9.2% 
lipodystrophy in 2.1%. toxic hepatitis in 1.4%. paresthesias in 2.1% 
anemia in 2.8% and gastrointestinal intolerance in 11.4%. 16 (1 1.4%) 
patients needed hospital admission: 2 due to herpe5 zoster, 2 due to 
non-Hodgkin lyniphoma, 7 due to nephrohthiasis, 2 due to diarrhea 
and 3 due to lipodystrophy. N o  patient suffered opportunistic infec- 
tions or died during the follow-up. Good conipliance was observed 
in 81% of cases. 
Conclusions: (1) Good immunologic and virologic outconm 
were observed after 18-month follow-up in patients with HAART. 
(2) Overall clinical status was maintained during the period. 
